Pertuzumab-dpzb is now considered an interchangeable biosimilar to pertuzumab as part of treatment combinations in multiple ...

The EMA’s recommendation follows evidence that the targeted therapy improves progression-free survival in patients whose ...

The FDA approved pertuzumab-dpzb (Poherdy) as the first biosimilar for its reference product Perjeta, a monoclonal antibody ...

The findings came from analyses of two national cancer registries. ILC accounts for about 10% of all newly diagnosed breast ...

Endocrine therapy is generally recommended for patients with HR+/HER2-metastatic breast cancer, with the exception of those ...

The DESTINY-Breast11 (DB-11) and DESTINY-Breast05 (DB-05) trials, presented at the European Society for Medical Oncology ...

Pertuzumab-dpzb is the first interchangeable biosimilar to pertuzumab, enhancing treatment accessibility for HER2-positive ...

The U.S. Food and Drug Administration (FDA) approved Poherdy (pertuzumab-dpzb) as the first interchangeable biosimilar to ...

The agreement with EirGenix grants Sandoz exclusive rights to commercialize proposed biosimilar of pertuzumab for treatment ...

Poherdy is the first FDA-approved interchangeable biosimilar to Perjeta for HER2-positive breast cancer, potentially expanding access and reducing costs. Approved for use in combination with ...

In terms of prognostic risk factors, HER2 positivity, BM surgical resection, and diagnosis after 2014 were associated with ...

Breast cancer advancements include targeted therapies, oral medications for ER-positive/HER2-negative populations, and ...